Vor Biopharma (NASDAQ:VOR) Trading Down 8.2% – Time to Sell?

Vor Biopharma Inc. (NASDAQ:VOR) shares were down 8.2% during trading on Wednesday . The company traded as low as $20.41 and last traded at $20.2050. Approximately 428,626 shares were traded during trading, a decline of 59% from the average daily volume of 1,056,572 shares. The stock had previously closed at $22.00.

Analysts Set New Price Targets

Several brokerages have recently weighed in on VOR. Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Weiss Ratings raised Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, September 14th. Finally, Wedbush raised their price target on shares of Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 12th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.38.

Vor Biopharma Price Performance

The firm’s 50-day moving average price is $22.08 and its two-hundred day moving average price is $17.77.

Vor Biopharma (NASDAQ:VOR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, research analysts expect that Vor Biopharma Inc. will post -2.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in VOR. Fcpm Iii Services B.V. raised its stake in Vor Biopharma by 852.8% in the fourth quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after buying an additional 3,237,714 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in shares of Vor Biopharma during the fourth quarter worth about $33,275,000. NEXTBio Capital Management LP acquired a new position in shares of Vor Biopharma during the fourth quarter valued at about $13,080,000. Braidwell LP increased its holdings in shares of Vor Biopharma by 22.8% during the second quarter. Braidwell LP now owns 573,104 shares of the company’s stock valued at $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Finally, Findell Capital Management LLC purchased a new position in shares of Vor Biopharma in the 4th quarter valued at approximately $3,021,000. 97.29% of the stock is owned by institutional investors and hedge funds.

About Vor Biopharma

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing treatments for patients with hematologic malignancies, including acute myeloid leukemia (AML). The company combines engineered hematopoietic stem cell therapies with targeted cancer medicines in an effort to improve the selectivity and effectiveness of treatment.

Vor’s lead program, trem-cel (formerly known as VOR33), is an investigational gene-edited hematopoietic stem cell therapy designed to eliminate the CD33 protein from blood-forming stem cells.